CN110225781B - 噻唑衍生物及其应用 - Google Patents

噻唑衍生物及其应用 Download PDF

Info

Publication number
CN110225781B
CN110225781B CN201880005802.8A CN201880005802A CN110225781B CN 110225781 B CN110225781 B CN 110225781B CN 201880005802 A CN201880005802 A CN 201880005802A CN 110225781 B CN110225781 B CN 110225781B
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
stereoisomer
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880005802.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN110225781A (zh
Inventor
贺海鹰
江志赶
石卫华
夏建华
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huinuo Biomedical Technology Hangzhou Co ltd
Original Assignee
Huinuo Biomedical Technology Hangzhou Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huinuo Biomedical Technology Hangzhou Co ltd filed Critical Huinuo Biomedical Technology Hangzhou Co ltd
Publication of CN110225781A publication Critical patent/CN110225781A/zh
Application granted granted Critical
Publication of CN110225781B publication Critical patent/CN110225781B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201880005802.8A 2017-01-09 2018-01-09 噻唑衍生物及其应用 Active CN110225781B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710014893 2017-01-09
CN2017100148939 2017-01-09
PCT/CN2018/071964 WO2018127207A1 (zh) 2017-01-09 2018-01-09 噻唑衍生物及其应用

Publications (2)

Publication Number Publication Date
CN110225781A CN110225781A (zh) 2019-09-10
CN110225781B true CN110225781B (zh) 2022-05-17

Family

ID=62789152

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880005802.8A Active CN110225781B (zh) 2017-01-09 2018-01-09 噻唑衍生物及其应用

Country Status (5)

Country Link
US (1) US10647710B2 (enExample)
EP (1) EP3566749A4 (enExample)
JP (1) JP7150343B2 (enExample)
CN (1) CN110225781B (enExample)
WO (1) WO2018127207A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR113344A1 (es) 2017-10-05 2020-04-22 Innovative Molecules Gmbh Enantiómeros de una serie de compuestos antivirales
KR102535452B1 (ko) * 2018-07-06 2023-05-26 파에노 테라퓨틱스 씨오., 엘티디. 티아졸 화합물의 결정형 및 이의 응용
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
WO2025082442A1 (zh) * 2023-10-17 2025-04-24 辉诺生物医药科技（杭州）有限公司 (r)-5-卤素-2,3-二氢-1h-茚-2-羧酸的合成方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1434812A (zh) * 1999-12-23 2003-08-06 拜尔公司 噻唑基酰胺衍生物
DE10210319A1 (de) * 2002-03-08 2003-09-18 Bayer Ag Thiazolylcarbonyl-Derivate
DE10226048A1 (de) * 2002-06-12 2003-12-24 Bayer Ag Thiazolylsulfonamide
CN101115755A (zh) * 2005-02-11 2008-01-30 弗·哈夫曼-拉罗切有限公司 作为mglur2拮抗剂的吡唑并-嘧啶衍生物
CN101151019A (zh) * 2005-03-30 2008-03-26 艾库里斯有限及两合公司 N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺的药物制剂
WO2015197763A1 (en) * 2014-06-26 2015-12-30 Deutsches Krebsforschungszentrum Topical application for an anti-hsv antibody

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE455104T1 (de) * 2001-11-01 2010-01-15 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1434812A (zh) * 1999-12-23 2003-08-06 拜尔公司 噻唑基酰胺衍生物
DE10210319A1 (de) * 2002-03-08 2003-09-18 Bayer Ag Thiazolylcarbonyl-Derivate
DE10226048A1 (de) * 2002-06-12 2003-12-24 Bayer Ag Thiazolylsulfonamide
CN101115755A (zh) * 2005-02-11 2008-01-30 弗·哈夫曼-拉罗切有限公司 作为mglur2拮抗剂的吡唑并-嘧啶衍生物
CN101151019A (zh) * 2005-03-30 2008-03-26 艾库里斯有限及两合公司 N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺的药物制剂
WO2015197763A1 (en) * 2014-06-26 2015-12-30 Deutsches Krebsforschungszentrum Topical application for an anti-hsv antibody

Also Published As

Publication number Publication date
WO2018127207A1 (zh) 2018-07-12
EP3566749A4 (en) 2020-09-23
CN110225781A (zh) 2019-09-10
US10647710B2 (en) 2020-05-12
JP7150343B2 (ja) 2022-10-11
JP2020504184A (ja) 2020-02-06
EP3566749A1 (en) 2019-11-13
US20190375744A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
JP6754505B2 (ja) Ａｓｋ１阻害剤、その調製方法および使用
CN105837576B (zh) Btk抑制剂
JP6717457B2 (ja) Ｗｅｅ１阻害剤としての１，２−ジヒドロ−３Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−３−オン誘導体
CN110623958B (zh) 抗流感病毒嘧啶衍生物
JP6724246B2 (ja) チオフェン化合物、その合成方法及び医療における応用
CN110225781B (zh) 噻唑衍生物及其应用
WO2018133866A1 (zh) 作为ask1抑制剂的吡啶衍生物及其制备方法和应用
WO2018192493A1 (zh) 作为pcsk9抑制剂的哌啶类化合物
JP6836693B2 (ja) Ａ２ａ受容体アンタゴニストとしての縮合環誘導体
RS61913B1 (sr) Triciklično jedinjenje i njegova primena
JP7083836B2 (ja) アゼチジン誘導体
EP3498715B1 (en) Anti-hcmv virus compound
JP2018513199A (ja) イミダゾール系化合物
HK40009263A (en) Azetidine derivative
HK40003826A (en) Anti-influenza virus pyrimidine derivatives
HK40003826B (en) Anti-influenza virus pyrimidine derivatives
HK40009263B (zh) 氮杂环丁烷衍生物
EA038176B1 (ru) Производные пирроло-[1,2,5]бензотиадиазепина и их применение для лечения заболевания, вызванного вирусом гепатита в
HK40004140A (en) Fgfr4 inhibitor and preparation method and use thereof
HK40004140B (en) Fgfr4 inhibitor and preparation method and use thereof
HK40001993A (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
HK40001993B (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20211104

Address after: 310018 room 1-404, Heda Medicine Valley Center, No. 291, Fucheng Road, Xiasha street, Hangzhou Economic and Technological Development Zone, Hangzhou, Zhejiang Province

Applicant after: Huinuo biomedical technology (Hangzhou) Co.,Ltd.

Address before: Room 218, No. 9 Commercial Office Building, Gaoxin Road, Nanjing High-tech Development Zone, Jiangsu Province

Applicant before: Nanjing Mingde New Drug Development Co.,Ltd.

GR01 Patent grant
GR01 Patent grant